Phase 2 Brain Cancer Trial, Recruiting NCT06710249 Sponsor: Peter Siesjö Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT06710249
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 79 years old
  • People who have a known or suspected brain tumour (such as a tumour that has spread from elsewhere in the body, a meningioma, or a glioma) that is causing swelling in the brain and related symptoms
  • People who are alert and oriented, scoring 14 or 15 on a standard consciousness assessment called the Glasgow Coma Scale (confirm with trial site)
  • People who are relatively functional in daily life, meeting a standard medical performance rating of 0 to 2 out of 5 (confirm with trial site)
  • People who are already receiving or are planned to receive cortisone (steroid) treatment for their condition
  • People who are able to give their informed consent to participate in the trial

Who may not be able to join:

  • People who have an allergy to egg yolk
  • People whose brain swelling has caused a significant shift of brain structures more than 5mm from the centre of the brain (confirm with trial site)
  • People who score 13 or below on the Glasgow Coma Scale, meaning they have a reduced level of consciousness
  • People whose only symptom from the brain swelling is epilepsy (seizures)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +46705655778

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Peter Siesjö
Registry
ClinicalTrials.gov
Start date
27 January 2024
Est. completion
1 January 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Change of neurological symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov